Deutsche Bank sets Neurocrine stock with $138 price target
Deutsche Bank (ETR:DBKGn) began coverage on Neurocrine Biosciences (NASDAQ:NBIX) stock, assigning a Hold rating and setting a price target of $138. The bank's analyst noted that with a current market ...
Why Neurocrine Biosciences Stock Sank Today
Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences ...
UBS cuts Neurocrine Bio. stock target to $154, maintains Buy rating
UBS analyst Ashwani Verma adjusted the price target for Neurocrine Biosciences (NASDAQ:NBIX) to $154 from the previous $176, while continuing to recommend the stock as a Buy. Currently trading at $118 ...